首页|Identification of a NovelEHBP1-METFusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib
Identification of a NovelEHBP1-METFusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Wiley
As an aggressive tumor, intrahepatic cholangiocarcinoma (ICC) originates in the epithelium of the bile duct and has a poor prognosis. The therapeutic options for ICC are challenging and limited because of poor response to chemotherapy and the lack of targeted therapy. Here we report on a 41-year-old female patient with ICC withEHBP1-METfusion and multiple intrahepatic metastases responding to crizotinib. Next-generation sequencing-based tumor mutation profiling was performed on the tumor biopsy and circulating tumor DNA from plasma. A novelEHBP1-METfusion was identified and confirmed by Sanger sequencing. Immunohistochemistry of biopsy sample also revealed c-MET positivity. Subsequently, the patient started treatment with MET inhibitor crizotinib. Magnetic resonance imaging scan demonstrated a partial response for 8 months. To the best of our knowledge, this is the first clinical case report of a patient withMET-rearranged ICC successfully treated with crizotinib. This case suggests that crizotinib may be a promising treatment option for patients with ICC withMETfusion, warranting further clinical investigation. Key Points
NSTL
Wiley
